The Union alleges that Merck subcontracted – i.e., outsourced – its members’ jobs by contracting with foreign manufacturers to produce Janumet and then Case 2:15-cv-05374-GAM Document 36 Filed 01/26/17 Page 2 of 12
Wages & economic policyOfficial statement
Merck spent significant resources supporting the 2017 Republican Tax Law through lobbying disclosures
Lobbying disclosures show Merck spent significant resources supporting the bill, and Merck’s former CEO Kenneth Frazier repeatedly pressed decision-makers on taxes.7 Following a January 2017 meeting with.
Lobbying disclosures show Merck spent significant resources supporting the bill, and Merck’s former CEO Kenneth Frazier repeatedly pressed decision-makers on taxes.7 Following a January 2017 meeting with
Lobbying disclosures show Merck spent significant resources supporting the bill, and Merck’s former CEO Kenneth Frazier repeatedly pressed decision-makers on taxes.7 Following a January 2017 meeting with President Trump, Mr. Frazier said he and other pharmaceutical executives and lobbyists had focused their discussion on tax policy.8 Following a February 2017 meeting between President Trump and manufacturing CEOs, Mr. Frazier again said they had discussed changes to the tax code.9 The February meeting came shortly after Mr. Frazier signed a letter to House and Senate leadership supporting the push for new tax legislation.10 The letter Mr. Frazier signed was organized by a group—American Made Coalition—that Merck was a member of and that was formed specifically to advocate for changes to tax law.11 Additionally, in December 2017, after the Senate first passed the tax law, Merck was listed in a Senate Finance Committee press release as supporting the legislation.12
Lobbying disclosures show Merck spent significant resources supporting the bill, and Merck’s former CEO Kenneth Frazier repeatedly pressed decision-makers on taxes.7 Following a January 2017 meeting with President Trump, Mr. Frazier said he and other pharmaceutical executives and lobbyists had focused their discussion on tax policy.8 Following a February 2017 meeting between President Trump and manufacturing CEOs, Mr. Frazier again said they had discussed changes to the tax code.9 The February meeting came shortly after Mr. Frazier signed a letter to House and Senate leadership supporting the push for new tax legislation.10 The letter Mr. Frazier signed was organized by a group—American Made Coalition—that Merck was a member of and that was formed specifically to advocate for changes to tax law.11 Additionally, in December 2017, after the Senate first passed the tax law, Merck was listed in a Senate Finance Committee press release as supporting the legislation.12
Lobbying disclosures show Merck spent significant resources supporting the bill, and Merck’s former CEO Kenneth Frazier repeatedly pressed decision-makers on taxes.7 Following a January 2017 meeting with
Lobbying disclosures show Merck spent significant resources supporting the bill, and Merck’s former CEO Kenneth Frazier repeatedly pressed decision-makers on taxes in 2017.11 Following a January
Lobbying disclosures show Merck spent significant resources supporting the bill, and Merck’s former CEO Kenneth Frazier repeatedly pressed decision-makers on taxes in 2017.11 Following a January 2017 meeting with President Trump, Mr. Frazier said he and other pharmaceutical executives and lobbyists had focused their discussion on tax policy.12 Following a February 2017 meeting between President Trump and manufacturing CEOs, Mr. Frazier again said they had discussed changes to the tax code.13 The February meeting came shortly after Mr. Frazier signed a letter to House and Senate leadership supporting the push for new tax legislation.14 The letter Mr. Frazier signed was organized by a group—American Made Coalition—that Merck was a member of and that was formed specifically to advocate for changes to tax law.15 Additionally, in December 2017, after the Senate first passed the tax law, Merck was listed in a Senate Finance Committee press release as supporting the legislation.16 The American public deserves to understand why Merck, a multinational pharmaceutical corporation with annual sales of $48 billion, paid a lower tax rate than a postal service worker or a preschool teacher.
Ukraine & RussiaConfirmed
Merck KGaA still operating in Russia
Merck KGaA continues operating and actively hiring in Russia, restricting transactions in Health Care Germany.
Merck KGaA still operating and actively hiring in Russia; restrict transactions Health Care Germany
ManufacturingConfirmed
Merck — expands domestic production
As part of it’s $70 billion domestic investment over the next several years, Merck has announced four manufacturing projects across the United States in 2025, totaling $6 billion.
As part of it’s $70 billion domestic investment over the next several years, Merck has announced four manufacturing projects across the United States in 2025, totaling $6 billion.